Press

Nov, 2018 - Press

TG Therapeutics announces Phase I study of novel BTK inhibitor, TG-1701, in patients with relapsed or refractory B-cell malignancies is open for Enrollment

Read More

Jan, 2018 - Press

TG Therapeutics, Jiangsu Hengrui announce agreement For BTK inhibitor program for treatment of hematologic malignancies

Read More